Navigation Links
NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
Date:1/23/2009

Anticipates Full Year 2008 Revenue of Approximately $250 Million

Announces Full Year 2009 Revenue Guidance of $345 Million to $350 Million

SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, today announced preliminary unaudited financial results for the full year ended December 31, 2008 and provided financial guidance for the full year 2009.

NuVasive anticipates full year 2008 revenue of approximately $250 million. The Company also expects to exceed its Osteocel(R) guidance for 2008 with $10 million in revenue and is now launching the product through its exclusive sales force. The Company announced anticipated full year 2008 revenue in advance of its National Sales Meeting, which will take place January 23-24, 2009. The Company anticipates full year 2008 earnings per share of $0.07 - $0.09 excluding in-process research and development costs and other adjustments related to a one-time leasehold termination charge, transitional support costs related to the Company's ERP system, and intellectual property litigation expense.

NuVasive also announced revenue guidance for the full year 2009. The Company expects full year 2009 revenue to be in the range of $345 million to $350 million. Osteocel revenue in the fourth quarter 2008 included approximately $5 million in sales to former distributors of Osiris Therapeutics, Inc. (Nasdaq: OSIR). As the Company launches the Osteocel product through its exclusive sales force, it will not have the benefit of this revenue in first quarter 2009. As a result, overall first quarter 2009 revenue should be flat compared to fourth quarte
'/>"/>

SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
2. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
3. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
4. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
5. NuVasive Acquires First Stem Cell Bone Graft Substitute
6. NuVasive Reports First Quarter 2008 Financial Results
7. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
8. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
9. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
10. NuVasive to Present at BIOCOM Investor Conference 2007
11. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... The North America Endpoint Security Market ... in North America with analysis and forecast of revenue. ... billion in 2014 to $4.77 billion by 2019, at ... Browse through the TOC of the North America Endpoint ... in-depth analysis provided. It also provides a glimpse of ...
(Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
(Date:8/1/2014)... NY) Scientists at Albert Einstein College of ... that aid in digestion help keep the intestinal lining ... Immunity , could yield new therapies for inflammatory bowel ... , The research involved the intestinal microbiome, which contains ... in promoting or preventing disease is a major emerging ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Oxford ... company develops biomarkers. Its products include CytoSure heamatological ... +SNP Array, CytoSure ISCA UPD array, CytoSure ISCA ... array. OGT offers services, such as targeted sequencing ... service, miRNA analysis, gene expression analysis, cytosure services ...
(Date:8/1/2014)... Kathleen Doheny HealthDay Reporter ... Birth control pills containing high doses of estrogen, along ... breast cancer in women under 50, new preliminary ... explained lead researcher Elisabeth Beaber, a staff scientist at ... of these formulations increase breast cancer risk while other ...
Breaking Medicine News(10 mins):Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 2Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 3Health News:North America End-Point Security Market is Expected to Reach $4 billion in 2019 - New Report by MicroMarket Monitor 4Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:'Normal' bacteria vital for keeping intestinal lining intact 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
(Date:7/31/2014)... SAN DIEGO, July 31, 2014  ResMed Inc. (NYSE: ... and for the fiscal year ended June 30, 2014.  Revenue ... quarter ended June 30, 2013 (a 1 percent decrease on ... increase of 20 percent compared to the quarter ended June ... $0.61, an increase of 22 percent compared to the quarter ...
(Date:7/31/2014)... Inc. (the "Company") (Nasdaq: PCYC ) today reported ... 30, 2014. Financial Results for the Six Months ... for the quarter ended June 30, 2014 increased to $113.0 ... 2013 primarily due to IMBRUVICA ® (ibrutinib) net product ... the six months ended June 30, 2014 increased to $232.4 ...
(Date:7/31/2014)... VIEW, Calif. , July 31, 2014 /PRNewswire/ ... today provided an update on its pipeline and ... 2014, Alexza expects to initiate a Phase 2a ... is being developed for the management of patients ... two new Staccato -based product candidates for ...
Breaking Medicine Technology:RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 2RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 3RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 4RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 5RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 6RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 7RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 8RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 9RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 10RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 11RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 12RESMED Inc. Announces Results for the Fourth Quarter and Fiscal Year 2014 13Pharmacyclics Reports Second Quarter 2014 Results 2Pharmacyclics Reports Second Quarter 2014 Results 3Pharmacyclics Reports Second Quarter 2014 Results 4Pharmacyclics Reports Second Quarter 2014 Results 5Pharmacyclics Reports Second Quarter 2014 Results 6Pharmacyclics Reports Second Quarter 2014 Results 7Pharmacyclics Reports Second Quarter 2014 Results 8Pharmacyclics Reports Second Quarter 2014 Results 9Pharmacyclics Reports Second Quarter 2014 Results 10Pharmacyclics Reports Second Quarter 2014 Results 11Pharmacyclics Reports Second Quarter 2014 Results 12Pharmacyclics Reports Second Quarter 2014 Results 13Pharmacyclics Reports Second Quarter 2014 Results 14Pharmacyclics Reports Second Quarter 2014 Results 15Pharmacyclics Reports Second Quarter 2014 Results 16Pharmacyclics Reports Second Quarter 2014 Results 17Pharmacyclics Reports Second Quarter 2014 Results 18Pharmacyclics Reports Second Quarter 2014 Results 19Pharmacyclics Reports Second Quarter 2014 Results 20Pharmacyclics Reports Second Quarter 2014 Results 21Pharmacyclics Reports Second Quarter 2014 Results 22Pharmacyclics Reports Second Quarter 2014 Results 23Pharmacyclics Reports Second Quarter 2014 Results 24
... Mass., Oct. 13 Boston Scientific Corporation (NYSE: ... launch of its Journey™ Guidewire, an innovative 0.014" ... peripheral angioplasty procedures.  The Journey Guidewire strengthens Boston ... physician needs in treating arteries below the knee. ...
... SKILLMAN, N.J., Oct. 13 ConvaTec, a world-leading developer ... hospital care, today announced that its top executives have ... MedTech Conference , the premier medical technology conference for ... from around the world. Well known ...
Cached Medicine Technology:Boston Scientific Announces Global Launch of Journey™ Guidewire 2Boston Scientific Announces Global Launch of Journey™ Guidewire 3ConvaTec to Present at AdvaMed 2010: The MedTech Conference 2
... Fat Harvest, Wash & Transfer System is ... make fat transfer procedures simpler for the ... the need for an office-based technique. LipiVage™ ... is no longer a need to centrifuge, ...
... Type B) Injectable Solution, the only Botulinum ... demonstrated in numerous published studies to be ... Delivered as a purified, ready-to-use solution, ... a simpler way to significantly reduce abnormal ...
... BOTOX® Cosmetic is a simple, nonsurgical, physician-administered ... severe frown lines between the brows in ... age. It is the only treatment of ... Drug Administration (FDA). BOTOX® Cosmetic is ...
Inquire...
Medicine Products: